BIORA THERAPEUTICS, INC. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020
Operating Activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Gain from discontinued operations
Depreciation and amortization
Stock-based compensation expense
Loss on extinguishment of convertible notes
Non-cash revenue reserve
Loss on extinguishment of convertible notes and accrued interest
Amortization of debt discount
Inducement Loss on Convertible Note
Inventory write-down
Inducement loss on convertible notes
Loss on disposal of property and equipment
Change in fair value of derivative liability
Impairment of property and equipment
Change in fair value of derivative liabilities
Loss (gain) on investment in Enumera Molecular, Inc.
Changes in operating assets and liabilities:
Accounts receivable, net
Inventory
Income tax receivable
Prepaid expenses and other current assets
Other assets
Accounts payable
Accrued expenses and other liabilities
Income tax payable
Other long-term liabilities

Net cash used in operating activities - continuing operations
Net cash provided by operating activities - discontinued operations

Net cash used in operating activities
Investing Activities:
Purchases of property and equipment
Proceeds from sale of property and equipment
Net cash used in investing activities - continuing operations
Net cash provided by investing activities - discontinued operations
Net cash provided by (used in) investing activities
Financing Activities:
Proceeds from issuance of common stock
Proceeds from issuance of common stock warrants
Tax payments to settle restricted stock units
Proceeds from issuance of common stock under employee stock purchase plan
Proceeds from issuance of senior secured convertible notes
Proceeds from exercise of common stock warrants
Proceeds from issuance of Series B Preferred Stock and warrant, net
Payments for financing of insurance premiums
Payments for offering costs
Principal payments on mortgages payable
Principal payments on capital lease obligations
Net cash provided by financing activities - continuing operations
Net cash used in financing activities - discontinued operations
Net cash provided by financing activities
Net decrease in cash, cash equivalents and restricted cash
Cash and cash equivalents at end of period
Cash, cash equivalents and restricted cash at beginning of period
Cash, cash equivalents and restricted cash at end of period
Supplemental disclosure of cash flow information:
Cash paid for interest
Cash paid for income taxes
Supplemental schedule of non-cash investing and financing activities:
Exchange of note payable for convertible notes
Issuance of common stock in settlement of accrued expenses
Conversion of convertible notes to common stock and warrants
Issuance Of Common Stock Upon Conversion Of Interest
Issuance of preferred stock in settlement of interest payable
Related party troubled debt restructuring
Exchange of convertible notes for senior secured convertible notes and warrants
Conversion of accrued interest in exchange for senior secured convertible notes
Investment in Enumera Molecular Inc. in exchange for assets
Issuance of common stock and re-priced warrants upon settlement of accrued interest
Issuance of warrants upon settlement of accrued interest
Leased assets obtained in exchange for operating lease liabilities
Change in fair value of re-priced equity classified warrants
Equity financing issuance costs incurred but not paid
Debt issuance costs incurred but not paid
Issuance of stock options in settlement of accrued bonuses
Issuance of common stock in settlement in accrued expenses
Purchases of property and equipment in accounts payable
Settlement of warrant liability

Comments